Regulus Therapeutics (RGLS) Misses Q2 EPS by 8c
Tweet
Share
E-mail
Get Alerts RGLS Hot Sheet
Join SI Premium – FREE
Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.41), $0.08 worse than the analyst estimate of ($0.33).
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Marchex (MCHX) Reports In-Line Q2 EPS
- Stantec (STN) Tops Q2 EPS by 47c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
